The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Official Title: A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Study ID: NCT02626234
Brief Summary: the study aim to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group, Atlanta, Georgia, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Novartis Investigative Site, Vienna, , Austria
Novartis Investigative Site, Edegem, Antwerpen, Belgium
Novartis Investigative Site, Brno, , Czechia
Novartis Investigative Site, Ioannina, GR, Greece
Novartis Investigative Site, Athens, , Greece
Novartis Investigative Site, Milano, MI, Italy
Novartis Investigative Site, Candiolo, TO, Italy
Novartis Investigative Site, Bologna, , Italy
Novartis Investigative Site, Napoli, , Italy
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, London, , United Kingdom
Novartis Investigative Site, Manchester, , United Kingdom
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR